معرفی
Prof. Peter Mol is a Professor of Drug Regulatory Science at the University of Groningen's Faculty of Medical Sciences, affiliated with the University Medical Center Groningen (UMCG). He holds key roles at the European Medicines Agency (EMA) as a Dutch member of the Committee for Medicinal Products for Human Use (CHMP) and serves as a clinical assessor at the Dutch Medicines Evaluation Board (CBG-MEB). His expertise spans pharmacovigilance, drug safety, regulatory science, and pharmacoepidemiology.
Research focuses on adverse drug reactions, regulatory decision-making for neurodegenerative diseases, and real-world evidence in drug development. He has supervised a PhD project on neurodegenerative diseases and organized major conferences like the ICPE International Conference on Pharmacoepidemiology. Awards include recognition for top scientific papers in Drug Safety (2017-2019).
Notable activities include presenting on patient preferences in drug regulation and delivering an inaugural lecture on knowledge exchange between science and regulatory authorities. His work emphasizes collaboration between academia, regulators, and industry to improve drug evaluation and patient outcomes.
